跳至主要内容
临床试验/EUCTR2021-003895-15-DK
EUCTR2021-003895-15-DK进行中(未招募)1 期

Impact of human papillomavirus (HPV) vaccination on burden of disease in patients with actinic keratosis - a double-blind randomized controlled trial - VAXAK Trial

Bispebjerg Hospital, Department of Dermatology and Venereology0 个研究点目标入组 70 人开始时间: 2021年10月7日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
70

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Subjects who meet all the following criteria are eligible to participate in this study:
  • 1.High AK burden, defined as =15 AK lesions in the included test area (50-100 cm2) at baseline
  • 2.Test area does not involve the ala nasi, eyelids, nasolabial folds, or periauricular skin
  • 3.>18 years of age at baseline
  • 4.Fitzpatrick skin phototype I-IV
  • 5.Legally competent, able to give verbal and written informed consent
  • 6.Subject is willing to participate and can comply with protocol requirements including the refraining from other therapy (with the exception of KC treatment) in the test area for the duration of the trial.
  • 7.Women of childbearing potential must be confirmed not pregnant by a negative urine pregnancy test prior to trial treatment and be on effective contraception until discontinuation of the vaccine therapy. Additional pregnancy testing will not be conducted unless pregnancy is suspected.
  • (Female subjects are considered of childbearing potential unless they have been hysterectomized or have undergone tubal ligation or have been post-menopausal for at least one year prior to first visit. Effective contraception is IUD or hormonal contraception as specified in the protocol)
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 5
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 65

排除标准

  • Subjects meeting any of the following criteria are not eligible to participate in this study:
  • 1.Known or suspected immunosuppression (by disease or immunosupressive drug)
  • 2.History of vaccine-related allergic reactions or known allergy to Gardasil®9 ingredients or yeast
  • 3.Previously vaccinated with any HPV vaccine
  • 4.History of keloids
  • 5.Other skin diseases present in the test area at baseline
  • 6.Lactating or pregnant women

研究者

发起方
Bispebjerg Hospital, Department of Dermatology and Venereology

相似试验